company background image
ILMN

Illumina WBAG:ILMN Stock Report

Last Price

€197.58

Market Cap

€31.1b

7D

4.3%

1Y

-35.2%

Updated

25 Jan, 2023

Data

Company Financials +

ILMN Stock Overview

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.

ILMN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Illumina, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Illumina
Historical stock prices
Current Share PriceUS$197.58
52 Week HighUS$338.40
52 Week LowUS$171.20
Beta1.13
1 Month Change8.48%
3 Month Change-16.42%
1 Year Change-35.22%
3 Year Change-30.89%
5 Year Change1.32%
Change since IPO26.17%

Recent News & Updates

Recent updates

Shareholder Returns

ILMNAT Life SciencesAT Market
7D4.3%-2.5%1.1%
1Y-35.2%-19.5%-11.0%

Return vs Industry: ILMN underperformed the Austrian Life Sciences industry which returned -18.6% over the past year.

Return vs Market: ILMN underperformed the Austrian Market which returned -10.5% over the past year.

Price Volatility

Is ILMN's price volatile compared to industry and market?
ILMN volatility
ILMN Average Weekly Movement6.2%
Life Sciences Industry Average Movement6.1%
Market Average Movement4.4%
10% most volatile stocks in AT Market8.7%
10% least volatile stocks in AT Market2.5%

Stable Share Price: ILMN is more volatile than 75% of Austrian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ILMN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Austrian stocks.

About the Company

FoundedEmployeesCEOWebsite
19989,825Francis deSouzahttps://www.illumina.com

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services.

Illumina, Inc. Fundamentals Summary

How do Illumina's earnings and revenue compare to its market cap?
ILMN fundamental statistics
Market Cap€31.10b
Earnings (TTM)-€3.82b
Revenue (TTM)€4.32b

7.2x

P/S Ratio

-8.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ILMN income statement (TTM)
RevenueUS$4.70b
Cost of RevenueUS$1.42b
Gross ProfitUS$3.28b
Other ExpensesUS$7.44b
Earnings-US$4.15b

Last Reported Earnings

Oct 02, 2022

Next Earnings Date

Feb 07, 2023

Earnings per share (EPS)-26.40
Gross Margin69.83%
Net Profit Margin-88.36%
Debt/Equity Ratio25.9%

How did ILMN perform over the long term?

See historical performance and comparison